As­traZeneca says CMS guid­ance around IRA ex­emp­tions is 'un­law­ful' in lat­est court brief

As­traZeneca ar­gued in court on Fri­day that the gov­ern­ment’s rules around which drugs may be ex­empt from Medicare price ne­go­ti­a­tions un­der the In­fla­tion Re­duc­tion Act are un­law­ful and put it at risk of “im­mi­nent harm.”

Un­der the cur­rent guide­lines, 10 drugs will be sub­ject to gov­ern­ment price ne­go­ti­a­tion start­ing in 2026 if they have no gener­ic or biosim­i­lar com­pe­ti­tion. But un­der the gov­ern­ment’s cur­rent in­ter­pre­ta­tion, it isn’t enough to have a com­peti­tor on the mar­ket. CMS must de­ter­mine that “bona fide” mar­ket­ing ex­ists for the gener­ic based on a num­ber of fac­tors, in­clud­ing the num­ber of pre­scrip­tions for Medicare ben­e­fi­cia­ries.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER